SCHEMBL4375437

SCHEMBL4375437

COc1ccc(CCC(=O)N2CCN(c3ccncc3)CC2)cc1OC

nearest known ligand 0.72

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.72
GFER P55789 3/20 0.60
KDM4E B2RXH2 3/20 0.55
POLB P06746 1/20 0.55
MEN1 O00255 4/20 0.54
ALDH1A1 P00352 2/20 0.53
HPGD P15428 2/20 0.53
HSD17B10 Q99714 2/20 0.53
CASP1 P29466 1/20 0.53
CASP7 P55210 1/20 0.53
HTT P42858 2/20 0.52
LMNA P02545 1/20 0.52
GAA P10253 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
NPC1 O15118 1/20 0.52
MC4R P32245 1/20 0.51
NAMPT P43490 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4377694 0.93 KMT2A (0.63) KMT2AGFERKDM4EPOLBMEN1
SCHEMBL4377690 0.89 KMT2A (0.72) KMT2AGFERKDM4EPOLBMEN1
SCHEMBL4375389 0.85 FKBP1A (0.65) KMT2AGFERPOLBMEN1ALDH1A1
SCHEMBL4378642 0.83 L3MBTL1 (0.57) KMT2AGFERKDM4EPOLBMEN1
SCHEMBL13636195 0.81 ROCK2 (0.54) KMT2AGFERMEN1ALDH1A1LMNA
SCHEMBL4376079 0.81 MEN1 (0.77) KMT2AKDM4EMEN1ALDH1A1HTT
SCHEMBL14218122 0.80 KMT2A (0.62) KMT2AGFERKDM4EMEN1ALDH1A1
SCHEMBL2292827 0.80 KMT2A (0.66) KMT2AGFERPOLBMEN1HTT
SCHEMBL2292606 0.80 KMT2A (0.66) KMT2AGFERPOLBMEN1ALDH1A1
SCHEMBL12944656 0.79 KMT2A (0.62) KMT2AGFERKDM4EPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP claimed
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP disclosed
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113968-A1 Substituted piperazines and diazepanes HRH3, HRH4, HRH1 KMT2A 295/4885GFER 3843/4885KDM4E 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.